Trial reportBlood cancer journal2021
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia.
Open access · goldAbstract readClinical TrialMulticenter Study
In one paragraph
Trial report in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 62 citations in OpenAlex.
- Safety of liposomal daunorubicin-cytarabine (CPX-351) in secondary AML: Japanese phase 1/2 study and global phase 3 study.International journal of hematology · 2025Trial
- Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation.American journal of hematology · 2025Trial
- Association between gene mutations and outcomes in Japanese high-risk AML patients: a phase 1/2 study of NS-87/CPX-351.International journal of hematology · 2025Trial
- Trial
- Article
- Biomarkers and advances in AML-MRC: from bench to bedside.Annals of hematology · 2026Review
- Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy.Annals of hematology · 2026Article
- Real-world experience with CPX-351 for secondary acute myeloid leukaemia: Comparison with FLAG-IDA in a propensity score matching analysis.British journal of haematology · 2026Article
- Determinants of survival in patients treated with CPX-351 for acute myeloid leukemia.Frontiers in oncology · 2026Article
- Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.Blood cancer journal · 2025Article
- Recent advances in drug delivery and treatment strategies for acute myeloid leukemia.International journal of pharmaceutics · 2025Review
- Review
- Feasibility of allogeneic stem cell transplantation (HSCT) in patients with acute myeloid leukemia previously treated with CPX-351: report from a single center.Annals of hematology · 2025Article
- Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management.American journal of hematology · 2025Review
- Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia - long-term follow-up with focus on younger patients.Blood cancer journal · 2025Article
- How I treat secondary acute myeloid leukemia.Blood · 2025Review
- Azacitidine in combination with HAG for newly diagnosed and relapsed/refractory AML: a prospective cohort study.Annals of hematology · 2025Article
- Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS.Blood advances · 2025Article
- Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy.Blood advances · 2024Article
- Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient.Hematology. American Society of Hematology. Education Program · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
49 authors at 20 institutions in 1 country.
Christina Rautenberg *Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine-University, Duesseldorf, Germany.
Friedrich Stölzel *Medizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany.ORCID 0000-0003-0653-5332
Christoph RölligMedizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany.
Matthias StelljesDepartment of Medicine A, University Hospital Münster, Münster, Germany.
Verena GaidzikDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
Michael LausekerInstitute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilians-University, Munich, Germany.ORCID 0000-0002-6662-7127
Oliver KriegeDepartment of Medicine III, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.
Mareike VerbeekDepartment of Medicine III, Technical University of Munich, Munich, Germany.
Julia Marie UnglaubDepartment of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
Felicitas TholDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Stefan W KrauseDepartment V for Internal Medicine, University Hospital Erlangen, Erlangen, Germany.ORCID 0000-0002-5259-4651
Mathias HänelDepartment of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany.
Charlotte NeuerburgDepartment of Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany.
Vladan VucinicLeipzig: Department of Hematology and Cell Therapy, Medical Oncology, Hemostaseology, Leipzig, Germany.
Christian-Friedrich JehnDepartment of Hematology, Oncology and Stem Cell Transplantation, Asklepios Clinic St. Georg, Hamburg, Germany.
Julia SevermannDepartment of Hematology and Stem Cell Transplantation, West German Cancer Center Essen, University Hospital Essen, Essen, Germany.
Maxi WassClinic and Policlinic for Internal Medicine IV, University Hospital Halle (Saale), Halle (Saale), Germany.
Lars FranseckyDepartmenf for Internal Medicine II, University Schleswig-Holstein, Kiel, Germany.
Jens ChemnitzGemeinschaftsklinikum Mittelrhein GGmbH, Koblenz, Germany.
Udo HoltickDepartment I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Kerstin Schäfer-EckartDepartment of Internal Medicine V, Oncology and Hematology, Klinikum Nürnberg, Nürnberg, Germany.
Josephine SchröderClinic for Heaematology and Stem Cell Transplantation HELIOS Clinic Berlin-Buch GmbH, Berlin, Germany.
Sabrina KrausDivision of Hematology and Oncology, Department of Internal Medicine II, University of Würzburg, Medical Center, Würzburg, Germany.
William KrügerClinic and Policlinic for Internal Medicine C, Hematology and Oncology, University of Greifswald, Greifswald, Germany.
Ulrich KaiserDepartment of Hematology and Oncology, St. Bernward Krankenhaus, Hildesheim, Germany.
Sebastian SchollDepartment of Internal Medicine II, Hematology and Oncology, University Hospital Jena, Jena, Germany.
Kathrin KochDepartment of Medicine III, Technical University of Munich, Munich, Germany.
Lea HenningDepartment of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine-University, Duesseldorf, Germany.
Guido KobbeDepartment of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine-University, Duesseldorf, Germany.
Rainer HaasDepartment of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine-University, Duesseldorf, Germany.
Nael AlakelMedizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany.
Maximilian-Alexander RöhnertMedizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany.
Katja SockelMedizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany.ORCID 0000-0003-1732-7299
Maher HanounDepartment of Hematology and Stem Cell Transplantation, West German Cancer Center Essen, University Hospital Essen, Essen, Germany.
Uwe PlatzbeckerLeipzig: Department of Hematology and Cell Therapy, Medical Oncology, Hemostaseology, Leipzig, Germany.
Tobias A W HolderriedDepartment of Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany.
Anke MorgnerDepartment of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany.
Michael HeuserDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.ORCID 0000-0001-5318-9044
Tim SauerDepartment of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
Katharina S GötzeDepartment of Medicine III, Technical University of Munich, Munich, Germany.
Eva Wagner-DrouetDepartment of Medicine III, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.
Konstanze DöhnerDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
Hartmut DöhnerDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
Christoph SchliemannDepartment of Medicine A, University Hospital Münster, Münster, Germany.
Johannes ScheteligMedizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany.
Martin BornhäuserMedizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany.
Ulrich GermingDepartment of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine-University, Duesseldorf, Germany.
Thomas Schroeder *Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine-University, Duesseldorf, Germany. Thomas.schroeder@uk-essen.de.ORCID 0000-0002-1653-7959
Jan Moritz Middeke *Medizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany. Janmoritz.middeke@ukdd.de.ORCID 0000-0003-3250-293X
University Hospital Carl Gustav Carus · DEDüsseldorf University Hospital · DETechnical University of Munich · DEUniversity Hospital Ulm · DEEssen University Hospital · DEHeidelberg University · DEJohannes Gutenberg University Mainz · DEKlinikum Chemnitz · DEMedizinische Hochschule Hannover · DEUniversity Hospital Bonn · DEUniversity Hospital Leipzig · DEUniversity Hospital Münster · DEAsklepios Klinik St. Georg · DEChristian-Albrechts-Universität zu Kiel · DEGemeinschaftsklinikum Mittelrhein · DEHelios Hospital Berlin-Buch · DEJena University Hospital · DENuremberg Hospital · DESt. Bernward Krankenhaus · DEUniversitätsklinikum Erlangen · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the efficacy and toxicities of CPX-351 outside a clinical trial, we analyzed 188 patients (median age 65 years, range 26-80) treated for therapy-related acute myeloid leukemia (t-AML, 29%) or AML with myelodysplasia-related changes (AML-MRC, 70%). Eighty-six percent received one, 14% two induction cycles, and 10% received consolidation (representing 22% of patients with CR/CRi) with CPX-351. Following induction, CR/CRi rate was 47% including 64% of patients with available information achieving measurable residual disease (MRD) negativity (<10
Indexed as
Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteAdultAgedAged, 80 and overAllograftsCytarabineDaunorubicinDisease-Free SurvivalFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm, ResidualSurvival RateCPX-351CytarabineDaunorubicin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.